For example, a glycosylated variant of an anti-PD-L1 antibody with core-fucosylated N-glycans in its Fc region (92%) led to an improvement in binding to FcγRIIIa, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) activity against PD-L1+ cancer cells [86]. Here, CD274 is linked to cancer.